December 1987
Advocate;12/22/87, Issue 488, p26
Reports that the New York State Health Department will use a multimillion-dollar fund to buy the drug AZT for low-income people with AIDS or AIDS-related complex (ARC).


Related Articles

  • Timing of AZT. M.O.R. // Cortlandt Forum;03/25/97, Vol. 10 Issue 3, p139 

    Warns against the use of zidovudine monotherapy in newly diagnosed HIV patients. Drugs which could be combined with zidovudine to increase anti-HIV activity; Factors on which decisions about when to initiate treatment are usually based.

  • Combining acyclovir and zidovudine for AIDS patients. Donaldson Jr., Robert M.; Berkowitz, Henry D. // Cortlandt Forum;7/25/95, Vol. 8 Issue 7, p92 

    Discusses the use of acyclovir and zidovudine in the treatment of AIDS patients. Reduction in the initial development of opportunistic infections; Prolonged survival in patients with HIV; Side effects of a combination of zidovudine and acyclovir.

  • TIME RUNS OUT FOR AZT PROGRAM. Harding, Rick // Advocate;10/25/88, Issue 510, p10 

    Reports on the end of the United States federal program that provides free distribution of the AZT drug to AIDS patients. Implication of the program's closure on AIDS patients; Worth of the drug.

  • No significant side effects for minority patients who take AZT.  // AIDS Patient Care & STDs;Jun96, Vol. 10 Issue 3, p185 

    Details the effectiveness of AZT in the treatment of African-American patients with AIDS. Determination of racial or ethnic differences in the tolerance of AZT; Absence of significant side effects of the drug.

  • AZT: Prolonging Life But Not Stopping Death. Helquist, Michael // Advocate;3/3/87, Issue 467, p23 

    Reports that the medical advisers of the U.S. Food and Drug Administration have recommended in 1987 the licensing of AZT for sale to a restricted group of patients with AIDS or severe ARC. Initial results of studies on AZT; Benefits from taking AZT; Researchers' concerns about side effects.

  • Treatments for ADC. Helquist, Michael // Advocate;4/26/88, Issue 497, p36 

    Reports on information gathered from researches on the treatment of AIDS dementia complex. Focus on azidothymidine (AZT) and on the experimental drug peptide-T; Details of separate research studies on the two treatments.

  • New Report on AZT. Helquist, Michael // Advocate;1/17/89, Issue 516, p30 

    Reports on a study indicating that azidothymidine (AZT) can reverse the deterioration in mental and cognitive capabilities often experienced by individuals with AIDS or AIDS-related complex. Support for anecdotal reports on the benefits of the antiviral drug; Details of the study.

  • AZT. Vohr, Hans-Werner // Encyclopedic Reference of Immunotoxicology;2005, p83 

    The article presents an encyclopedia entry for AZT. AZT or zidovudine is an antiviral drug used in treatment of acquired immunodefiency syndrome.

  • Point: Subsidized HIV/AIDS Drugs Should be Universal. Parent, Gabrielle // Canadian Points of View: Subsidizing HIV/AIDS Drugs;12/01/2018, p2 

    The article presents an argument for subsidization of HIV and AIDS drugs. It is the author's opinion that governments, drug companies, and health care providers must work together to make HIV and AIDS drugs available to all infected individuals. Highly active antiretroviral therapy (HAART), the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics